Kenvue is a global leader in aging skin, including launching the first prescription retinoid in 1971, first perfecting the process to stabilize retinol, and filing and bringing the first retinol patent to the United States in 1990. We have been conducting specialized research for several decades.
“Retinol is the most commonly used over-the-counter anti-aging cosmetic ingredient recommended by dermatologists and sought after by consumers. However, not all retinol products are created equal.” said Menas Kisoulis, Senior Director of Global Science Engagement at Kenvue. “This ingredient is difficult to formulate and stabilize, but Kenvue has particular expertise with over 30 years of experience in formulating and patenting retinol products. “We demonstrate how a stabilized bioactive retinol formulation can effectively promote clinical skin health benefits.”
The patented formula allows for slow release of retinol into the skin.
Kenvue's data analysis included six vehicle-controlled studies of 0.1% stabilized bioactive retinol in women aged 30 years and older with signs of mild to moderate UV-induced photodamage . In all studies, a single dermatologist researcher used a numerical scale to measure overall facial photodamage and site-specific photodamage, such as forehead wrinkles, crow's feet, and age spots, as a baseline. and assessed at weeks 4, 8, and 12. Tolerability was also assessed.
A total of 237 participants received daily treatment with retinol and 234 received vehicle only.
The researchers found that retinol caused greater improvements from baseline in all signs of photoaging compared to vehicle, and the changes were evident from week 4 and continued through week 12. Of the few participants who experienced irritation, all events were mild to moderate and transient, and the authors found that both retinol and its vehicle were well-tolerated throughout his 12 weeks, with no severe It was concluded that there were no signs of severe irritation.
“This vehicle-controlled analysis provides compelling new evidence that this ingredient effectively reduces signs of skin aging without causing irritation,” said the study's lead author, Dermatology. said Patricia K. Faris, MD, MS, FAAD4, clinical associate professor in the department. She received her doctorate from Tulane University School of Medicine and practices as a dermatologist in Louisiana. “These findings provide further support for the use of products containing Neutrogena® Rapid Wrinkle Repair Line 5, which targets signs of aging with 0.1% stabilized bioactive retinol.”
If you would like to learn more about the research or schedule an interview with Dr. Faris or Dr. Menas Kisoulis, please contact your Kenvue R&D media representative.
relevant content
The beauty of retinoids in cosmetic chemistry
Johnson & Johnson names new consumer health company Kenvue